Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?

Objective: Immune checkpoint inhibitors (ICIs) are front-line treatment options for NSCLC. ICI therapy is associated with a risk of immune-related adverse events (irAEs). Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening irAE. Previous studies have demonstrated that asthma and...

Full description

Saved in:
Bibliographic Details
Main Authors: David Spillane, Carmela Pepe, Goulnar Kasymjanova, Diane Cruiziat, Sara Cohen, Jeremy Naimer, Jason Agulnik
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/32/5/259
Tags: Add Tag
No Tags, Be the first to tag this record!